Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Publication year range
2.
Bull Soc Pathol Exot ; 107(1): 27-30, 2014 Feb.
Article in French | MEDLINE | ID: mdl-24390976

ABSTRACT

Burkina Faso is a sub-saharan African country completely included in the meningococcal meningitis belt. The western part of the country suffered from many meningococcal A epidemics, in spite of reactive collective campaigns with polysaccharide A vaccine. On 6th December 2010, Burkina Faso was the first African country to conduct a collective vaccination campaign of all the 1-29 years old population with a new conjugated meningococcal Avaccine (MenAfriVac™). Before this campaign, in Western Burkina (4,064,928 inhabitants, 27.5% of total population), a rehearsal of the staff of all peripheral medical laboratories has been conducted, with delivery of laboratory equipment, reactants, and possibility to transfer CSF specimens at the central level to confirm bacteriologic species in cause by latex, culture and PCR analysis. For this campaign, an administrative coverage of 100.3% was reached. A nearly complete disappearance of meningitis due to meningococcus A was recorded, but an increase of cases due to meningococcus X, W135. With the increase of quality of surveillance, and MenAfriVac™ vaccination showed its beneficial effect on meningococcus A meningitis. If we want however to impact on the number of recorded acute bacteriological meningitis, we will have to use multi-antigenic, if possible conjugated, meningococcal vaccines against locally circulating meningococcal species, the number of pneumococcal meningitis being contained by the recent inclusion in EPI of a 13-valent conjugated pneumococcal vaccine.


Subject(s)
Disease Notification/statistics & numerical data , Meningitis, Meningococcal/prevention & control , Meningococcal Vaccines , Vaccines, Conjugate , Burkina Faso , Humans , Retrospective Studies
3.
Rev Med Interne ; 35(1): 56-9, 2014 Jan.
Article in French | MEDLINE | ID: mdl-24075627

ABSTRACT

INTRODUCTION: Treatment of giant cell arteritis is based on prolonged corticosteroid therapy but adverse side effects are common especially in the elderly. CASE REPORTS: We report three patients with giant cell vasculitis treated by tocilizumab, an interleukin-6 receptor antibody, owing to resistance or intolerance to corticosteroid therapy. A favorable outcome was rapidly observed both on clinical and biological data allowing a corticoid therapy sparing. CONCLUSION: Tocilizumab is a promising treatment of giant cell arteritis but controlled trials are needed to confirm its efficacy.


Subject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , Giant Cell Arteritis/drug therapy , Adrenal Cortex Hormones/therapeutic use , Aged , Drug Resistance/drug effects , Female , Humans , Treatment Outcome
4.
Afr Health Sci ; 13(2): 287-94, 2013 Jun.
Article in English | MEDLINE | ID: mdl-24235926

ABSTRACT

BACKGROUND: There is no data on long-term benefit of once-a-day antiretroviral therapy (ART) with combination of DDI, 3TC and EFV to allow its use in future therapeutic strategies. OBJECTIVES: To assess 24-month immuno-virological, adherence, tolerance, and effectiveness of a once-a-day ART with DDI, 3TC and EFV. METHODS: A phase 2 open trial including 51 children aged from 30 months to 15 years, monitored a once-a-day regimen for 24 months from 2006 to 2008 in the Departement de Pediatrie du CHUSS, at Bobo-Dioulasso in Burkina Faso. We tested immunological and virological response, adherence, tolerance and resistance of the treatment. RESULTS: Children with CD4 >25% at 24 months were 67.4% (33/49) CI 95% [54%, 80%]. The proportion of children with viral plasma RNA <300 cp / ml at 24 months of treatment was 81.6 % (40/49) CI [68.0% 91.2%]. Good adherence was obtained with more than 88% adherence > 95% over the 24 months. Drugs were well tolerated. CONCLUSIONS: Given the limited number of antiretroviral drugs available in Africa and the inadequacy of laboratory monitoring in support program, once-a-day treatment and especially the DDI-based combination strategies could be an attractive operational option.


Subject(s)
Anti-HIV Agents/administration & dosage , Benzoxazines/administration & dosage , Didanosine/administration & dosage , HIV Infections/drug therapy , Lamivudine/administration & dosage , Medication Adherence , Adolescent , Africa , Alkynes , Anti-HIV Agents/pharmacokinetics , Benzoxazines/pharmacokinetics , CD4 Lymphocyte Count , Child , Child, Preschool , Confidence Intervals , Cyclopropanes , Didanosine/pharmacokinetics , Female , Humans , Lamivudine/pharmacokinetics , Male , RNA, Viral/drug effects , Surveys and Questionnaires , Viral Load/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL
...